-- Tandem Diabetes Care (TNDM) said Monday the US Food and Drug Administration has cleared Control-IQ+ automated insulin delivery technology for use in pregnancy complicated by type 1 diabetes mellitus, expanding its label indication.
Control-IQ+ powers both insulin delivery systems from Tandem - the t:slim X2 and Tandem Mobi, the firm said.
Price: $20.03, Change: $-0.33, Percent Change: -1.62%